Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Cell. Infect. Microbiol.

Sec. Clinical and Diagnostic Microbiology and Immunology

Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1661213

This article is part of the Research TopicExploring Clinical Application Scenarios of Metagenomic Next-Generation Sequencing for Pathogen DiagnosisView all 13 articles

Clinical Application of Metagenomic Next-Generation Sequencing in the diagnosis of severe pneumonia pathogens

Provisionally accepted
Ying  ZhangYing Zhang1Caitao  DongCaitao Dong2Raojuan  HuangRaojuan Huang3Jingdi  ChenJingdi Chen4Handong  ZouHandong Zou5Yang  LiuYang Liu6Mengmeng  GUOMengmeng GUO3Hang  GaoHang Gao5Quan  KeQuan Ke5Wei  WuWei Wu5*
  • 1Department of Vascular Surgery, Renmin Hospital of Wuhan University, Wuhan, China
  • 2Department of Urology, Renmin Hospital of Wuhan University, Wuhan, China
  • 3First Clinical College of Wuhan University, Wuhan University, Wuhan, China
  • 4Department of orthopedics, The Airborne Military Hospital, Wuhan, China
  • 5Department of Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China
  • 6Department of Critical Care Medicine, Xianfeng county people's hospital, En shi, China

The final, formatted version of the article will be published soon.

Background: Severe pneumonia is a significant cause of mortality among ICU patients. Metagenomic next-generation sequencing (mNGS) is an advanced, comprehensive, unbiased diagnostic tool for pathogen identification in infectious diseases. This study aimed to evaluate the clinical efficacy of mNGS for diagnosing severe pneumonia. Methods: This study retrospectively analyzed 323 patients with suspected severe pneumonia admitted to the intensive care unit (ICU) of Wuhan University Renmin Hospital between January 2022 and December 2023. Bronchoalveolar lavage fluid (BALF) samples were collected from all 323 patients, and blood samples were obtained from 80 patients. Both mNGS and conventional microbial testing (CMT) were performed on the collected BALF and blood samples to analyze the pathogen spectrum. The diagnostic performance of mNGS and CMT was systematically evaluated and compared. Results: The overall positivity rate of mNGS was significantly greater than that of CMT (93.5% vs. 55.7%, p < 0.001). mNGS demonstrated significantly greater sensitivity than did CMT (94.74% vs. 57.24%, p < 0.001) but lower specificity (26.32% vs. 68.42%, p < 0.01). mNGS identified 36 bacterial species, 14 fungal species, 7 viral species, and 1 Chlamydia species, whereas CMT detected 21 bacterial species and 9 fungal species. According to the pathogen spectrum, Klebsiella pneumoniae, Acinetobacter baumannii, and Candida albicans were the predominant pathogens associated with severe pneumonia. The detection rate of mixed infections was significantly higher with mNGS than with CMT (62.8% vs. 18.3%, p < 0.001). Conclusions: Compared with CMT methods, mNGS has significant advantages in pathogen detection for severe pneumonia. Owing to its broad detection range and high sensitivity, mNGS serves as a valuable complementary approach to traditional culture-based methods.

Keywords: Severe pneumonia, metagenomic next-generation sequencing, pathogen, ClinicalDiagnosis, Intensive Care Unit

Received: 07 Jul 2025; Accepted: 23 Oct 2025.

Copyright: © 2025 Zhang, Dong, Huang, Chen, Zou, Liu, GUO, Gao, Ke and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Wei Wu, 478994416@qq.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.